Neil Basu,Kristian Stefanov
Neil Basu
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study [0.03%]
针对类风湿关节炎TNF抑制治疗临床反应的脑激活预测标志物研究（PreCePra）：一项随机、多中心、双盲、安慰剂对照的Ⅲ期试验
Andreas Hess,Koray Tascilar,Hanna M Schenker et al.
Andreas Hess et al.
Background: Rheumatoid arthritis is an inflammatory disease frequently treated with TNF inhibitors. Little is known about predictors of response to TNF inhibitors. Because clinical response in rheumatoid arthritis is meas...
David Fl Liew,Claire E Owen
David Fl Liew
Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial [0.03%]
复发性多肌炎患者的sarilumab治疗：三期双盲随机对照试验中的患者报告结局指标
Vibeke Strand,Jerome Msihid,Jennifer Sloane et al.
Vibeke Strand et al.
Background: Sarilumab is approved for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. We aimed to evaluate the effect of saril...
The Lancet Rheumatology
The Lancet Rheumatology
Comparison of findings on contrast-enhanced MRI of the hand, wrist, and forefoot in healthy controls, two at-risk groups, and patients with rheumatoid arthritis: a cohort study [0.03%]
一项队列研究：健康人、两种高危人群和类风湿关节炎患者手、腕及前足对比剂增强MRI结果的比较
Dennis A Ton,Nikolet K den Hollander,Hanna W van Steenbergen et al.
Dennis A Ton et al.
Background: The sensitivity of MRI in detecting joint inflammation in rheumatoid arthritis is well known but its specificity is less discussed. It is important to prevent false positive results and consequent overdiagnosi...
Mami Tamai,Atsushi Kawakami
Mami Tamai
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis [0.03%]
风湿性关节炎的双重JAK和ROCK抑制及并发症
Fabiola Atzeni,James Galloway
Fabiola Atzeni
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial [0.03%]
一项随机、双盲、安慰剂对照的Ⅱ期临床试验：CPL'116治疗甲氨蝶呤疗效不足的类风湿关节炎患者效果研究——该药同时抑制JAK和ROCK
Maciej Wieczorek,Bartłomiej Kisiel,Dorota Włodarczyk et al.
Maciej Wieczorek et al.
Background: Janus kinase (JAK) inhibitors are an effective treatment option in rheumatoid arthritis and other autoimmune diseases. However, the use of JAK inhibitors is associated with increased total cholesterol, LDL cho...
Exposure to hydroxychloroquine in early pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study [0.03%]
瑞典系统性红斑狼疮患者早期妊娠期间接触羟氯喹与子痫前期和早产发病率的关系：全国基于人群的队列研究
Ngoc V Nguyen,Anna Sandström,Elisabet Svenungsson et al.
Ngoc V Nguyen et al.
Background: Pregnant women with systemic lupus erythematosus (SLE) have elevated risks of pre-eclampsia and pre-term delivery. Hydroxychloroquine, the mainstay treatment during pregnancy in women with SLE, is currently a ...